|Red yeast rice is the "+1" in this SuppVersity Mini-Series because it is actually a "statin". Similar effects, similar side effects and all that (probably) because of the similar structure of its lipid lowering active ingredient(s).|
While garlic, which will also be discussed in today's first installment of what is going to become a mini-series, also has the ability to decrease your HMG-CoA reductase activity, only RYR does that at a similar potency as statins do; which is why its use entails the risk of similar side effects as they have been reported for regular statin drugs Whether RYR is thus your best "natural alternative" is highly questionable.
On the other hand, the fact that the monacolins, the main bioactive compounds in RYR, is not debatable. Only recently, a meta-analysis by Li et al. (2014) reported no serious side effects and concluded based on 13 RCTs that "red yeast rice is an effective and relatively safe approach for dyslipidemia" (Li. 2014). Li et al. do yet also know that "further long-term, rigorously designed randomized controlled trials are still warranted before red yeast rice could be recommended to patients with dyslipidemia, especially as an alternative to statins" (Li. 2014).
|Figure 1: Effects of 1,200mg/d red yeast rice (RYR) on blood lipids in statin-intolerant subjects (left | Venro. 2010) and subject-dependent reductions in LDL in the latest meta-analysis of the effects of RYR (right | Li. 2014).|
Don't be a fool! This article is no statin or anti-cholesterol add. Nobody says that taking statins without a good reason would be wise. In fact, even the relatively well-tolerated RYR which works by the same mechanism, produced (albeit tolerable) muscle weakness and muscle pain as adverse effects in most clinical studies; a downside that points to the 'demusculizing' effects of HMG-CoA reductase inhibitors - even if the difference to placebo reached statistical significance only in few (albeit short-term) studies (Liu. 2006 & Li. 2014).Further evidence that, as so often, individuality is key comes from the differential effects in European, Asian and US subjects (see Figure 1 showing data from Li. 2014). The latter, however, may be explained by both, the genetic configuration of the subjects, and the high ingredient variability of commercially available RYR preparations of which a comparative analysis of 10 commercial red yeast rice products reports a >30-fold range in total monacolin content. The authors of said study also highlight:
"Furthermore, compared with the full spectrum of monacolins expected in a red yeast rice dietary supplement, with monacolin K representing 55% to 60%, 4 of the 10 products were >90% monacolin K, suggesting that they were actually food-grade red yeast rice “spiked” with lovastatin, the prescription statin that is chemically identical to monacolin K" (Mark. 2010).And Mark et al. are not the only ones reporting an intolerable degree of cutting in the snake oil industry. Similar results have been presented by Gordon et al. who tested 12 products that are regularly sold and consumed in the US and found total monacolin contents ranging from 0.31 to 11.15 mg/capsule. Just like Mark et al. Gordon et al. also found monacolin K (lovastatin | 0.10-10.09 mg/capsule), which could occur naturally, albeit not at very high doses, in many and the kidney-damaging citrinin in four of the twelve tested products (33%).
Garlic is a HMG-CoA inhibitor that doesn't have the problems of statins & RYR ...
...or, we simply don't know about them yet, because the currently available garlic supplements all suffer from the pathetic bioavailability of allicin (which is broken down enzymatically before it reaches your bloodstream | Lawson. 2001), which could - in very high doses that have not been tested in studies yet - possibly have similar negative side effects as the monocalins in RYR.
More recently, however, studies have suggested that allicin may not even be necessary for some of the beneficial effects of garlic. In particular, its general anti-oxidant and anti-inflammatory effects appear to be mediated mainly by S-allyl cysteine. Furthermore, "various chemical constituents in garlic products, including nonsulfur compounds such as saponins, may contribute to the essential biological activities of garlic" (Amagase. 2006) - including their anti-lipidemic effect.
I want to try it - What's the optimal dosing for garlic and RYR? While the evidence for the more powerful RYR is relatively conclusive and says that effective dosage(s) range from 600 and 3600 mg (depending on product quality and how significant your 'cholesterol-problem' is), reliable dosage suggestions are hard to make for garlic. In the previously cited recent review from Thailand (Thaipitakwong & Aramwit. 2016), the suggestion is 2–5 g of fresh garlic, 0.4–1.2 g of dried powder, 2–5 mg of oil and 300–1000 mg - "any other preparations should correspond to 4–12 mg of alliin or 2–5 mg of allicin" (ibid.). As previously pointed out, however, there's probably one study to refute the efficacy of real-food or supplemental garlic at the given dosages for every two studies that support it. Eventually, you will thus have to self-experiment to find out if and at which dosages garlic can exert a significant effect on your blood lipids.In contrast to their active ingredient, however, the efficacy of garlic and garlic supplements as anti-hyperlipidemic drugs is well-established. One of the most cited meta-analyses (39 RCTs with 2298 participants | Ried. 2013) found that, overall, garlic consumption caused significant changes in serum levels of total cholesterol (–15.25 mg/dl; p < 0.0001), LDL-C (–6.41 mg/dl; p = 0.02), and HDL-C (1.49 mg/dl; p = 0.02), whereas the triglyceride levels appeared to be unaffected (I will address this in a follow-up, but if you eat your garlic with fatty fish, this should address the triglyceride issue). In addition, a more recent meta-analysis revealed that it will also reduce the level of lipoprotein (a) in the blood of hyperlipidemic subjects (Sahebkar. 2016).
|Figure 2: Effects of garlic supplements on LDL (left, red) and HDL (right, green) according to a 2013 meta-analysis of 39 RCTs with 2298 participants (Ried. 2013) - the results have generally been confirmed more recently (Ried. 2016).|
- Amagase, Harunobu. "Clarifying the real bioactive constituents of garlic." The Journal of nutrition 136.3 (2006): 716S-725S.
- Gordon, et al. "Marked variability of monacolin levels in commercial red yeast rice products." Arch Intern Med 170.19 (2010): 1722-1727.
- Lawson, Larry D., and Z. Jonathan Wang. "Low allicin release from garlic supplements: a major problem due to the sensitivities of alliinase activity." Journal of agricultural and food chemistry 49.5 (2001): 2592-2599.
- Li, Yinhua, et al. "A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia." PloS one 9.6 (2014): e98611.
- Liu, Jianping, et al. "Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials." Chinese medicine 1.1 (2006): 1.
- Mark, David A. "All red yeast rice products are not created equal—or legal." The American journal of cardiology 106.3 (2010): 448.
- Venero, Carmelo V., et al. "Lipid-lowering efficacy of red yeast rice in a population intolerant to statins." The American journal of cardiology 105.5 (2010): 664-666.
- Sahebkar, Amirhossein, et al. "Effect of garlic on plasma lipoprotein (a) concentrations: A systematic review and meta-analysis of randomized controlled clinical trials." Nutrition 32.1 (2016): 33-40.
- Ried, Karin, Catherine Toben, and Peter Fakler. "Effect of garlic on serum lipids: an updated meta-analysis." Nutrition reviews 71.5 (2013): 282-299.
- Ried, Karin. "Garlic lowers blood pressure in hypertensive individuals, regulates serum cholesterol, and stimulates immunity: an updated meta-analysis and review." The Journal of nutrition 146.2 (2016): 389S-396S.